Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

This abstract contains subscription and access information for Wolters Kluwer Health journals but reports no research findings.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This study suggests that Gujian oral liquid may reduce osteoarthritis symptoms by regulating inflammation and catabolism through the TNF-α/NF-kappa B signaling pathway, as confirmed by both in vivo and in vitro experiments.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this study, oral JAK inhibitors were found to be significantly more effective than placebo in promoting hair regrowth among adults and adolescents with moderate-to-severe alopecia areata, although they were associated with an increased risk of adverse events.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

This review discusses the phytochemical and pharmacological properties of Jatropha dioica, highlighting its potential uses in traditional medicine and the need for more scientific validation of its effects.

In this study on New Zealand white rabbits, the researchers reported that a hair tonic formula combining bitter melon leaf and carrot extracts resulted in optimal hair growth, particularly at a 3:1 ratio and a concentration of 3%, without causing irritation.

In this study, applying water extracts of liquorice at a concentration of 2.5% to male rabbits led to the best rate of hair growth at 2.19 cm over 35 days, while a 5% concentration resulted in the greatest hair weight at 0.12 grams.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

This study found that microwave-assisted extraction significantly increased the yield of secondary metabolites, including phenolic and flavonoid content, from Nardostachys jatamansi, enhancing its anti-Alzheimer's potential compared to conventional extraction methods.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

JAK inhibitors might help treat alopecia areata.

This review compiles scientific data on Nyctanthes arbor-tristis Linn., highlighting its documented anti-inflammatory, anticancer, and hepatoprotective properties, among others, and recommends future research to further explore the plant's bioactive components and their potential applications.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

This review concludes that Tamarix aphylla, used traditionally for ailments such as tuberculosis and hepatitis, demonstrates various pharmacological activities, including antidiabetic and wound-healing effects, but stresses the need for further research to confirm its safety and effectiveness in humans.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

In this study, a hair tonic containing black fungus extract was shown to have antifungal activity against Malassezia furfur, with the 70% extract concentration providing the strongest effect.

In this experimental study, researchers developed a hair tonic using green spinach leaves and assessed its feasibility based on vitamin content and sensory characteristics, finding that the tonic was generally liked by panelists in hedonic tests.

This study found that Geranium Sibiricum L extract may promote hair growth by increasing cell proliferation and migration while modulating cytokine expression in human dermal papilla cells under stress conditions.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

This review compiles current experimental research on Alzheimer's and cognitive impairment models, highlighting the potential of *Polygonum multiflorum* for treating neurological disorders and suggesting a foundation for future clinical trials.